ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy

News
Video

Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy

Clinicians from around the world have convened in Salt Lake City, Utah, for the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). One of those experts is Anat Loewenstein, MD. Prof Loewenstein is director of the division of ophthalmology at Tel Aviv Medical Center in Israel. She is also a Modern Retina editorial advisory board member.

In a conversation with the Eye Care Network, Prof Loewenstein described her presentation, results from a Delphi consensus on the management of diabetic retinopathy. The consensus group was composed of a smaller cohort of five retina specialists, as well as a larger group of health care providers (including more retina experts). This population of practitioners were administered three surveys, which they used to record results on the current treatment protocols and outcomes for patients with diabetes.

"There were a few topics that achieved consensus," Prof Loewenstein said. Physicians in the cohort agreed on many of the unmet needs of patients, especially those which cause patients to have a high treatment burden and poor visual acuity. "One topic that achieved high consensus was the lack of possibility of very early intervention and noninvasive therapy," Prof Loewenstein said. "Another unmet need considered the lack of addressing additional pathological and paramechanistic paths." In particular, Prof Loewenstein said, diabetic macular oedema may need to be treated via more than just one pathway, in order to combat its multi-factorial origin. "That might bring along better visual acuity outcome, maybe with decreased burden for our patients," Prof Loewenstein said.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.